Want to see ARDT full AI Analyst Report?
Top Page
Ardent Health Partners, Inc.
(NYSE:ARDT)
Select Model
Select Model
Rating:64Neutral
Price Target:
$11.00
▼(-2.65% Downside)
Action:Reiterated
Date:08/06/26
The score is held back primarily by weakening recent fundamentals (TTM revenue decline, thin margins, and a sharp pullback in free cash flow). Offsetting this, the technical setup is positive (price above key moving averages with supportive momentum), and the latest earnings call was execution-focused with reaffirmed EBITDA guidance and expanded cost-savings actions. Valuation appears reasonable on P/E, though no dividend yield data is available.
Positive Factors
Liquidity and Leverage
Strong liquidity and low net leverage give Ardent meaningful financial flexibility to absorb operating volatility, fund ambulatory and high-margin service investments, and continue targeted efficiency initiatives without relying heavily on incremental borrowing.
Negative Factors
Recent Revenue and Margin Weakness
The sharp TTM revenue contraction and thin, declining margins reduce Ardent’s ability to absorb cost inflation or payer pressure. Continued weakness would constrain internally funded investment and make earnings more sensitive to changes in volumes and reimbursement.
Read all positive and negative factors
Positive Factors
Negative Factors
Liquidity and Leverage
Strong liquidity and low net leverage give Ardent meaningful financial flexibility to absorb operating volatility, fund ambulatory and high-margin service investments, and continue targeted efficiency initiatives without relying heavily on incremental borrowing.
Read all positive factors
Ardent Health Partners, Inc. (ARDT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.70B
Dividend YieldN/A
Average Volume (3M)482.48K
Price to Earnings (P/E)21.9
Beta (1Y)0.56
Revenue Growth3.34%
EPS Growth-69.26%
CountryUS
Employees22,350
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.55
Shares Outstanding141,045,910
10 Day Avg. Volume610,552
30 Day Avg. Volume482,482
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)0.74
Price to Sales (P/S)0.20
P/FCF Ratio4.81
Enterprise Value/Market Cap1.96
Enterprise Value/Revenue0.52
Enterprise Value/Gross Profit1.74
Enterprise Value/Ebitda8.32
Forecast
1Y Price Target
$12.29Price Target Upside8.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)0.95
Revenue Forecast (FY)$6.46B
Ardent Health Partners, Inc. Business Overview & Revenue Model
Company Description
Ardent Health, Inc. owns and operates a network of hospitals and clinics that provides healthcare services in the United States. The company offers general and specialty services, including internal medicine, general surgery, cardiology, oncology,...
How the Company Makes Money
Ardent Health Partners primarily makes money by delivering healthcare services and receiving reimbursement for those services from a mix of payers. The largest revenue stream is patient service revenue generated when its hospitals and outpatient f...
Ardent Health Partners, Inc. Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The earnings call presented a balanced but constructive view: management acknowledged notable near-term volume headwinds (April–May softness, exchange-related pressure and mix-driven revenue declines) but highlighted strong cash generation, a disciplined cost and IMPACT program that raised savings targets to over $70M, concrete payer contract gains (one renewal adding $5M–$10M of EBITDA), significant reductions in contract labor (down 42%), and early operational/technology wins (virtual care and ambient documentation). Management reiterated confidence in meeting full-year adjusted EBITDA guidance by offsetting an estimated ~$25M volume headwind with $20M–$30M of identified actions, and emphasized stronger Q3 prospects as savings run-rate ramps. Given the number and materiality of actionable positives and the firm plan to offset volume pressures, the tone was constructive and execution-focused despite ongoing macro risks.Positive Updates
IMPACT Program Momentum and Cost Savings
IMPACT savings target increased to over $70 million for 2026 (up from $55M prior target). Company expects $15M–$20M of incremental 2026 savings from structural changes (annualized $30M–$35M) and $5M–$10M of incremental 2026 EBITDA from payer recontracting — collectively expected to offset ~ $25M volume headwind.
Negative Updates
Volume Softness in Early Quarter
Broad-based volume weakness in April–May: surgeries down ~5% and admissions down ~2% in that period. For Q2, surgeries declined 2.9% and admissions declined 1% (management highlighted June/July improvement but July still below original expectations).
Read all updates
Q2-2026 Updates
Positive
Negative
IMPACT Program Momentum and Cost Savings
IMPACT savings target increased to over $70 million for 2026 (up from $55M prior target). Company expects $15M–$20M of incremental 2026 savings from structural changes (annualized $30M–$35M) and $5M–$10M of incremental 2026 EBITDA from payer recontracting — collectively expected to offset ~ $25M volume headwind.
Read all positive updates
Company Guidance
Ardent reaffirmed full‑year 2026 adjusted EBITDA guidance of $485–$535 million while biasing revenue to the low end of a $6.4–$6.7 billion range, reflecting an incorporated ~ $25 million volume headwind that management expects to fully offset with $20–$30 million of actions executed in Q2 (including $15–$20 million of incremental 2026 IMPACT savings and $5–$10 million of improved payer contracting).
IMPACT savings were increased to over $70 million for 2026 (up from prior $55M, originally $40M); the company expects the $20–$30 million benefit to be at full run rate entering Q3, supporting an improvement in Q3 adjusted EBITDA from Q2’s $115 million toward Q1’s $124 million.
Second‑quarter context: revenue $1.62 billion, adj. EBITDA $115M, surgeries -2.9% and admissions -1% in Q2 (April–May were worse: surgeries -5%, admissions -2%), adjusted admissions +2.5% YoY, net patient service revenue per adjusted admission -3.9% YoY, exchange admissions -8% (a $35M exchange headwind reaffirmed), SWB +0.7% YoY with contract labor spend down 42% YoY (contract labor = 2.2% of SW&B vs 3.8% prior), professional fees +10.4%, supplies +3.3%; liquidity: cash $724M, total debt $1.1B, available liquidity $992M, net leverage 0.8x, lease‑adjusted 2.6x.Ardent Health Partners, Inc. Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
57
Neutral
Cash Flow
51
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2018 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.41B | 6.32B | 5.97B | 5.41B | 5.13B | 4.16B |
| Gross Profit | 1.92B | 6.17B | 4.93B | 5.27B | 4.17B | 4.16B |
| EBITDA | 401.70M | 497.26M | 574.93M | 350.00M | 531.70M | 245.75M |
| Net Income | 78.23M | 135.81M | 210.34M | 50.29M | 188.91M | -143.02M |
Balance Sheet | ||||||
| Total Assets | 5.28B | 5.29B | 4.96B | 5.10B | 4.86B | 2.75B |
| Cash, Cash Equivalents and Short-Term Investments | 724.48M | 709.60M | 556.78M | 437.58M | 456.12M | 59.66M |
| Total Debt | 2.27B | 2.26B | 2.28B | 2.40B | 2.39B | 1.26B |
| Total Liabilities | 3.54B | 3.61B | 3.43B | 4.02B | 3.81B | 2.03B |
| Stockholders Equity | 1.35B | 1.69B | 1.13B | 670.90M | 639.05M | 331.64M |
Cash Flow | ||||||
| Free Cash Flow | 300.57M | 258.61M | 127.52M | 84.29M | -189.47M | -1.07M |
| Operating Cash Flow | 510.14M | 470.51M | 315.03M | 221.70M | -38.36M | 159.59M |
| Investing Cash Flow | -211.94M | -214.23M | -220.46M | -137.98M | 46.58M | -482.14M |
| Financing Cash Flow | -115.96M | -103.47M | 24.64M | -102.26M | -270.33M | 353.22M |
Ardent Health Partners, Inc. Technical Analysis
Positive
11.30
Price Trends
11.01
Positive
10.54
Positive
9.89
Positive
Market Momentum
0.39
Negative
69.00
Neutral
82.35
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARDT, the sentiment is Positive. The current price of 11.3 is above the 20-day moving average (MA) of 11.23, above the 50-day MA of 11.01, and above the 200-day MA of 9.89, indicating a bullish trend. The MACD of 0.39 indicates Negative momentum. The RSI at 69.00 is Neutral, neither overbought nor oversold. The STOCH value of 82.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARDT.
Ardent Health Partners, Inc. Risk Analysis
Ardent Health Partners, Inc. disclosed 55 risk factors in its most recent earnings report. Ardent Health Partners, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ardent Health Partners, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $10.78B | 7.42 | 20.66% | 0.44% | 10.05% | 28.53% | |
70 Outperform | $21.93B | 10.30 | 50.63% | ― | 5.43% | 65.86% | |
64 Neutral | $1.70B | 21.93 | 5.21% | ― | 3.34% | -69.26% | |
62 Neutral | $100.84B | 15.33 | -112.87% | 0.67% | 7.31% | 25.54% | |
56 Neutral | $401.89M | -19.16 | 0.90% | ― | 16.82% | -93.67% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
42 Neutral | $401.88M | -1.25 | 20.91% | 0.70% | -5.25% | ― |
* General Sector Average
ARDT
Ardent Health Partners, Inc.
12.36
-2.45
-16.54%
CYH
Community Health
2.91
-0.35
-10.74%
HCA
HCA Healthcare
467.31
30.14
6.89%
THC
Tenet Healthcare
270.63
63.72
30.80%
UHS
Universal Health
188.13
-19.60
-9.43%
AUNA
Auna S.A. Class A
5.03
-1.22
-19.52%
Ardent Health Partners, Inc. Corporate Events
Financial DisclosuresRegulatory Filings and Compliance
Ardent Health Revises Non-GAAP Metrics After SEC Review
Neutral
Sep 4, 2026
Ardent Health, Inc. has revised the non-GAAP financial measures in its Annual Report on Form 10-K for the year ended December 31, 2025, following discussions with the Securities and Exchange Commission’s Division of Corporation Finance. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.